Lupus nephritis is one of the most common serious manifestations of systemic lupus erythematosus (SLE). Antimalarial agents are part of the immunomodulatory regimen used to treat patients with SLE, but the role of antimalarial agents in the treatment of lupus nephritis has been underappreciated by nephrologists. In this Review, the authors discuss the use of chloroquine and hydroxychloroquine in the treatment of patients with SLE, focusing on those with lupus nephritis.
- Senq-J Lee
- Earl Silverman
- Joanne M. Bargman